MaxCyte, Inc.

MaxCyte, Inc.

MXCT·NASDAQ

$1.21

-0.22%
HealthcareMedical - Devices

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$129.08M
EPS-0.4200
P/E Ratio-2.87
Earnings Date08/12/2026

mxct

Net Debt

Last Annual Value

-2.12M

3-Year CAGR

-12%

5-Year CAGR

29%

10-Year CAGR

-6%

MaxCyte, Inc.

MaxCyte, Inc. Competitors Analysis of Net Debt

MXCT · NASDAQ
CompanyNet Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
MXCT logo
MaxCyte, Inc.
NASDAQ:MXCT
-2.12M
N/AN/AN/A 
-29.00M
N/AN/AN/A
38.28M
-35.3%N/A42.7%
-76.96M
N/AN/AN/A
HYPR logo
Hyperfine, Inc.
NASDAQ:HYPR
-34.77M
N/AN/AN/A
3.84M
N/AN/AN/A
-51.19M
N/AN/AN/A
14.00M
N/AN/AN/A
OWLT logo
Owlet, Inc.
NYSE:OWLT
-22.47M
N/AN/AN/A
279.33M
37.8%58.8%N/A
LNSR logo
LENSAR, Inc.
NASDAQ:LNSR
-10.24M
N/AN/AN/A
MaxCyte, Inc.

MaxCyte, Inc. Fair Value Envelope

MXCT · NASDAQ

Our analysis suggests that MXCT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.205, this represents a potential HIDDEN relative to our calculated worth for MaxCyte, Inc..

Intrinsic Value
Current Price: $1.205